Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) - Wikidata - wikimedia - TriplyDB

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

http://www.wikidata.org/entity/Q34467101

about

Probiotic fermented milk or isolated probiotic bacteria for primary prevention of cardiovascular disease in adults HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Lost in Translation (LiT): IUPHAR Review 6 Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl"Apolipoprotein A-V gene therapy for disease prevention / treatment:a critical analysis Pleiotropic effects of statins PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature Goals of statin therapy: three viewpoints The therapeutic role of niacin in dyslipidemia management 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target Implementing electronic clinical reminders for lipid management in patients with ischemic heart disease in the veterans health administration: QUERI Series.Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data.All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.The genesis of atherosclerosis and risk factors: a review.The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies.Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.A method to identify and validate mitochondrial modulators using mammalian cells and the worm C. elegans.Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?Current, new and future treatments in dyslipidaemia and atherosclerosis.Effects of aerobic and strength-based training on metabolic health indicators in older adults.Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials.Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics.Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Raising HDL cholesterol in women.Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials Niacin or ezetimibe for patients with, or at risk of coronary heart disease Lipid disorders in patients with type 2 diabetes. Meeting the challenges of early, aggressive treatment.Effects of a high-intensity intermittent training program on aerobic capacity and lipid profile in trained subjects Effect of statin therapy on the progression of coronary atherosclerosis.Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.

P2860

Q24185844-AB20ACDC-2126-4CD6-8863-DB3F7AEF90E1 Q24194514-0FF686D8-E125-418B-B840-A81B778CF5F7 Q24289150-8B50E8E1-4A86-49B6-9216-EF57AAE1AD1C Q24626884-6B790D7D-E393-4B54-9061-2C3D73CB8E60 Q24650533-0AF2BDF0-B6CB-4ABF-8237-40A3F0EA99E3 Q24658031-481886D6-FAB8-43C9-882F-E3154B9BB707 Q24793416-E2A74CEB-2A4C-4734-99B9-D530C957B847 Q24793512-3979962F-EDB2-4194-9AF6-6F07C85C8AD2 Q26775009-E574F302-AA09-4D08-9866-270B129BB253 Q26783220-8F465681-19F7-4601-B6D5-2107EB04BC0D Q27024799-D128AD31-805C-4FC2-ACC0-86A412A235FE Q28071946-44F98454-A667-4A1A-9BD3-DF6AC093700D Q28214326-D399DDF2-6D88-430C-946C-5DE48022EE0F Q28304559-1869C89C-01D3-4363-BB88-FBB9F6232A60 Q28572175-BE7B6193-B119-4518-BDBA-EDCB557E4DCE Q30370672-AA992AF1-9C9B-452A-B82C-88A4E1740B1D Q30482253-A8AF0DF8-3BF5-4364-89AC-CFA450491B77 Q31053321-91FF9E1A-D6C1-46CB-AB4B-446FF57BE531 Q31101617-ACBF1C29-3738-440A-8F90-25BC60D7AB6C Q32066896-5DE56231-8B94-418B-AA33-5D7096C466EB Q33440652-7E1A2DBB-AFA4-406C-A2A6-C67960D7309A Q33715404-D494DDFB-0918-4CC8-AF28-362AF1D27666 Q33749557-3533B839-6106-4496-9A9D-B031016187C1 Q33942357-DC07A2A7-744C-4D3A-B258-C06010827767 Q33993678-1841209A-1E7A-40F3-AA4F-5F07F2893083 Q34029164-5D3C26BD-54C5-409E-910A-548868417823 Q34030905-83B83359-BA82-4FB5-8900-90B12A32E957 Q34037840-030B319A-665F-4F8C-83F5-1B1B1ABA729F Q34041102-A30EAE0C-FE53-41E4-A058-33727A9F6735 Q34107382-AEC18411-B91E-49E3-B1C1-FBAE5ED2431E Q34169725-CAD27671-70A0-4798-9638-2136AABFDEDC Q34181381-B8406DD0-73E3-4E25-8624-60DD5A559061 Q34271942-FB9C4C30-A018-47E6-BEFA-719FC6373A9A Q34297213-27373B35-FA3D-4E8B-90B1-585499AF8A0B Q34300722-3FD1D369-A702-4C64-9B7F-6760185A7E99 Q34315710-8477B1C8-F39C-4202-97DF-57C1BDED5CF5 Q34394368-6B7DCEEA-D50F-449C-B1D9-2544E9EFA2CF Q34400201-03FDF7F5-C991-49E6-A265-F35A8C476ECF Q34417470-762C446F-B042-42A5-8E80-D78A546E301E Q34427770-C7C5B9DE-30E6-43B2-B51F-7E15ADBA7F2D

P2860

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

http://www.wikidata.org/entity/Q34467101

description

1998 nî lūn-bûn

@nan

1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Lipoprotein changes and reduct ...... imvastatin Survival Study (4S)

@ast

Lipoprotein changes and reduct ...... imvastatin Survival Study (4S)

@en

Lipoprotein changes and reduct ...... ian Simvastatin Survival Study

@nl

type

label

Lipoprotein changes and reduct ...... imvastatin Survival Study (4S)

@ast

Lipoprotein changes and reduct ...... imvastatin Survival Study (4S)

@en

Lipoprotein changes and reduct ...... ian Simvastatin Survival Study

@nl

prefLabel

Lipoprotein changes and reduct ...... imvastatin Survival Study (4S)

@ast

Lipoprotein changes and reduct ...... imvastatin Survival Study (4S)

@en

Lipoprotein changes and reduct ...... ian Simvastatin Survival Study

@nl

P1433

Q34467101-A6FD151E-0B31-4EE3-B4AA-265EE79002C7

P1476

Q34467101-668DBAA4-4780-494A-9361-BCBA666B6308

P2093

Q34467101-1A80F0D1-0D37-451F-8AA3-5E5B6CC9F771

Q34467101-1BEDF6AC-63D7-4116-A13A-DB295E5DC914

Q34467101-2CD87EC9-C0CC-41EF-99B0-3A9CC71DB2AF

Q34467101-48FC8D16-F62F-42DE-8DE3-F993E9C5996E

Q34467101-601F18C5-DDFB-44BF-BE79-F00CFA4D9E69

Q34467101-60356F5C-A37C-4E7A-A903-B97322030774

Q34467101-68A70EC6-D15C-4723-A1A2-5E135896873F

Q34467101-6E944DE0-7961-4F90-84A9-3AAD088C9882

Q34467101-7605D40D-1D11-4284-BE6C-F95F8099C553

Q34467101-818170C3-8069-4F5F-AC74-250F00E8258B

P304

Q34467101-B0CF4BCC-1173-49C4-B743-9BCC07D0CBD4

P31

Q34467101-29043A73-1FDF-46D6-87B2-1D8635E0A634

P356

Q34467101-4B1727CD-C9FA-4EE8-9DAC-AFB490E15422

P407

Q34467101-59B62F98-101D-4D07-AB80-66F7460254FC

P433

Q34467101-B90BEE0B-4EAA-4BCC-B2E1-61013D2F12F7

P478

Q34467101-7BFA7F10-51BF-4BBB-9FB1-79118F02FD3F

P50

Q34467101-40F666D8-AE2A-43BA-A6E3-51AF1D30ADEB

P577

Q34467101-4B35F06A-33AB-44F6-8A31-16A4BC70EC33

P698

Q34467101-75CA8D52-A474-4BE3-9E55-DC5BC0AD3286

P921

Q34467101-E2EA5B7B-5646-48BC-8587-B53998E278B3

P356

01.CIR.97.15.1453

P1433

P1476

Lipoprotein changes and reduct ...... imvastatin Survival Study (4S)

@en

P2093

Berg K

http://www.w3.org/2001/XMLSchema#string

Christophersen B

http://www.w3.org/2001/XMLSchema#string

Cook TJ

http://www.w3.org/2001/XMLSchema#string

Faergeman O

http://www.w3.org/2001/XMLSchema#string

Haghfelt T

http://www.w3.org/2001/XMLSchema#string

Miettinen T

http://www.w3.org/2001/XMLSchema#string

Musliner TA

http://www.w3.org/2001/XMLSchema#string

Olsson AG

http://www.w3.org/2001/XMLSchema#string

Pedersen TR

http://www.w3.org/2001/XMLSchema#string

Pyörälä K

http://www.w3.org/2001/XMLSchema#string

P304

1453-1460

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.97.15.1453

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

P577

1998-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9576425

http://www.w3.org/2001/XMLSchema#string

P921